Quarterly report pursuant to Section 13 or 15(d)

Organization and Principal Activities - Additional Information (Details)

v3.20.2
Organization and Principal Activities - Additional Information (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
May 14, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
Segment
$ / shares
shares
Dec. 31, 2019
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Date of incorporation       Apr. 21, 2003  
Headquartered in       South San Francisco  
Headquartered in state       CA  
Number of operating segments | Segment       1  
Estimated fair value of equity securities   $ 49,094 $ 49,094 $ 49,094  
Unrealized gain (loss) on equity securities     48,860 48,860  
Accumulated deficit   185,468 185,468 185,468 $ 195,745
Unrestricted cash, cash equivalents and marketable securities   207,000 207,000 $ 207,000  
Substantial doubt about going concern, within one year       false  
Minimum          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Period from issuance date of unaudited interim condensed financial statements       1 year  
Vaxcyte, Inc. | Vaxcyte Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Estimated fair value of equity securities   $ 49,100 49,100 $ 49,100  
Unrealized gain (loss) on equity securities     48,900 48,900  
Vaxcyte, Inc. | Vaxcyte Common Stock | Revaluation of Estimated Fair Value of Vaxcyte Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Unrealized gain (loss) on equity securities     49,100 49,100  
Vaxcyte, Inc. | Vaxcyte Common Stock | Revaluation of Prior Preferred Stock Warrant Converted to Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Unrealized gain (loss) on equity securities     $ (200) $ (200)  
Vaxcyte, Inc. | Equity Securities | Vaxcyte Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Public offering price per share | $ / shares   $ 16.00 $ 16.00 $ 16.00  
Number of shares held | shares   1,634,005 1,634,005 1,634,005  
Lock-up agreement expires month and year   2020-12      
Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Shares of common stock | shares     12,650,000    
Public Offering          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Gross proceeds from issuance of common stock $ 98,000        
Underwriting discounts and commissions and other offering expenses 6,600        
Net proceeds from issuance of common stock $ 91,400        
Public Offering | Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Shares of common stock | shares 12,650,000        
Public offering price per share | $ / shares $ 7.75        
Underwriters’ Option to Purchase Shares | Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Shares of common stock | shares 1,650,000